Isracann Biosciences Inc. - CEO, Phil Floucault
CEO, Phil Floucault
Source: Cowichan Valley Citizen
  • Isracann Bioscience (IPOT) announces that its first shipment of cannabis strains has cleared Israeli customs
  • The three strains shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper
  • Canadian quality cannabis will soon be grown in Israel and available to Israeli customers
  • Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products
  • Isracann Biosciences Inc. (IPOT) opened trading at C$0.045

Isracann Bioscience (IPOT) announces that its first shipment of cannabis strains has cleared Israeli customs and are being raised as mother stock.

“The Israeli market will now have access to premium Canadian high THC genetics,” notes CEO Phil Floucault.

“The three strains we shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper. All three strains have received a positive response from consumers in Canada, and I am looking forward to being able to make them available to the Israeli market.”

The three strains sent were developed as part of United Greeneries’ “Grass Roots” genetics program, which aims to produce novel high THC strains with commercially high yields.

Currently being sold as premium cannabis flower in Canada, the three strains represent some of the top performing genetics in United Greeneries’ catalogue. With the support of United Greeneries and Isracann, all three strains have been integrated into the Intelicanna facility and are being prepared as the initial Israeli mother stock.

Phil Floucault continues, “The planning and preparation by the teams in Canada and Israel made this genetics shipment happen smoothly. The growing teams are now fully engaged and working to expedite the process of scaling to full production. In the near term, Canadian quality cannabis will be grown in Israel and available to Israeli customers. Canadian genetics, Israeli grown.”

Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products.

Isracann Biosciences Inc. (IPOT) opened trading at C$0.045.


More From The Market Online

Differentiated cannabis stock bolsters brand portfolio

High Tide (TSXV:HITI), a leading cannabis retailer and differentiated stock, has added Queen of Bud to its international brand portfolio.

The Market Online’s Weekly Cannabis Report – March 15, 2024

Tilray Medical, a of Tilray Brands subsidiary, has been approved to supply Portugal’s first medical cannabis extract.

Portugal taps Tilray for country’s first medical cannabis extract

Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY), has been approved to supply Portugal's first medical cannabis extract.

Buzz on the Bullboards: The cannabis, tech and oil newsmakers

Investors look for the current and hot plays to capitalize on during a still-uncertain market, while other longer-term plays lose interest.